Concepts (101)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Thyroid Neoplasms | 12 | 2024 | 2326 | 1.700 |
Why?
|
Carcinoma, Neuroendocrine | 4 | 2024 | 338 | 1.120 |
Why?
|
Thyroid Nodule | 2 | 2024 | 760 | 1.080 |
Why?
|
Tongue Neoplasms | 2 | 2024 | 183 | 0.960 |
Why?
|
Adenocarcinoma, Follicular | 3 | 2023 | 323 | 0.950 |
Why?
|
RNA-Binding Protein FUS | 1 | 2024 | 75 | 0.900 |
Why?
|
Maxillary Sinus Neoplasms | 1 | 2022 | 39 | 0.830 |
Why?
|
Aphasia | 1 | 2024 | 192 | 0.830 |
Why?
|
Adenoma, Pleomorphic | 1 | 2021 | 75 | 0.740 |
Why?
|
Carcinoma, Medullary | 1 | 2020 | 115 | 0.670 |
Why?
|
Neoplasms, Glandular and Epithelial | 1 | 2022 | 487 | 0.620 |
Why?
|
Lymphatic Metastasis | 3 | 2023 | 2914 | 0.550 |
Why?
|
Anemia | 1 | 2024 | 1503 | 0.480 |
Why?
|
Thyroid Gland | 1 | 2020 | 1167 | 0.430 |
Why?
|
Immunohistochemistry | 4 | 2024 | 11063 | 0.410 |
Why?
|
Carcinoma, Squamous Cell | 4 | 2022 | 4019 | 0.410 |
Why?
|
Carcinoma, Papillary | 2 | 2023 | 784 | 0.290 |
Why?
|
Necrosis | 4 | 2022 | 1604 | 0.240 |
Why?
|
Mesenchymoma | 1 | 2024 | 49 | 0.230 |
Why?
|
Mitotic Index | 2 | 2021 | 161 | 0.220 |
Why?
|
GTP Phosphohydrolases | 2 | 2024 | 516 | 0.220 |
Why?
|
Carcinoma, Mucoepidermoid | 1 | 2023 | 89 | 0.210 |
Why?
|
Salivary Gland Neoplasms | 2 | 2023 | 304 | 0.200 |
Why?
|
Nomograms | 1 | 2024 | 227 | 0.200 |
Why?
|
Carcinoma, Adenoid Cystic | 1 | 2024 | 262 | 0.200 |
Why?
|
Carcinoma, Acinar Cell | 1 | 2022 | 62 | 0.190 |
Why?
|
Receptors, Steroid | 1 | 2022 | 156 | 0.190 |
Why?
|
Metaplasia | 1 | 2021 | 321 | 0.180 |
Why?
|
Retrospective Studies | 14 | 2024 | 79984 | 0.180 |
Why?
|
Pathology, Molecular | 1 | 2023 | 327 | 0.170 |
Why?
|
Iodine Radioisotopes | 1 | 2023 | 1032 | 0.160 |
Why?
|
Carcinoma, Ductal | 1 | 2019 | 97 | 0.160 |
Why?
|
Middle Aged | 12 | 2024 | 219192 | 0.160 |
Why?
|
Prognosis | 8 | 2024 | 29488 | 0.160 |
Why?
|
Lymphangioma | 1 | 2018 | 61 | 0.150 |
Why?
|
Breast Neoplasms | 1 | 2024 | 20992 | 0.140 |
Why?
|
Proto-Oncogene Proteins p21(ras) | 1 | 2024 | 1728 | 0.140 |
Why?
|
Oropharyngeal Neoplasms | 1 | 2022 | 491 | 0.130 |
Why?
|
Oncogene Proteins, Fusion | 1 | 2024 | 1594 | 0.130 |
Why?
|
Neoplasm Recurrence, Local | 3 | 2023 | 9245 | 0.130 |
Why?
|
Mouth Neoplasms | 1 | 2021 | 593 | 0.130 |
Why?
|
Breast | 1 | 2024 | 1961 | 0.130 |
Why?
|
Biopsy | 2 | 2024 | 6757 | 0.120 |
Why?
|
Male | 15 | 2024 | 358180 | 0.120 |
Why?
|
Thyroidectomy | 1 | 2020 | 902 | 0.120 |
Why?
|
Humans | 23 | 2024 | 757566 | 0.110 |
Why?
|
Mutation | 5 | 2024 | 29929 | 0.110 |
Why?
|
Histocompatibility Antigens Class I | 1 | 2019 | 1354 | 0.110 |
Why?
|
Aged, 80 and over | 6 | 2024 | 58558 | 0.100 |
Why?
|
Female | 12 | 2024 | 389943 | 0.100 |
Why?
|
Neoplasm Staging | 3 | 2023 | 11082 | 0.100 |
Why?
|
Cell Transformation, Neoplastic | 1 | 2021 | 2823 | 0.100 |
Why?
|
Diagnosis, Differential | 2 | 2024 | 12951 | 0.100 |
Why?
|
Antigens, Neoplasm | 1 | 2019 | 1994 | 0.100 |
Why?
|
Young Adult | 6 | 2024 | 58755 | 0.090 |
Why?
|
Head and Neck Neoplasms | 2 | 2022 | 2881 | 0.090 |
Why?
|
Cell Nucleus | 1 | 2019 | 2903 | 0.090 |
Why?
|
Ki-67 Antigen | 2 | 2023 | 630 | 0.090 |
Why?
|
Papillomavirus Infections | 1 | 2022 | 1602 | 0.090 |
Why?
|
Carcinoma | 1 | 2022 | 2330 | 0.090 |
Why?
|
Sarcoma | 1 | 2021 | 1784 | 0.090 |
Why?
|
Membrane Proteins | 2 | 2024 | 7840 | 0.080 |
Why?
|
Adolescent | 6 | 2024 | 87819 | 0.080 |
Why?
|
Cell Proliferation | 2 | 2023 | 10405 | 0.080 |
Why?
|
Adult | 10 | 2024 | 219725 | 0.070 |
Why?
|
Aged | 7 | 2024 | 167890 | 0.070 |
Why?
|
Tumor Microenvironment | 1 | 2019 | 3839 | 0.070 |
Why?
|
Receptors, Fibroblast Growth Factor | 1 | 2024 | 191 | 0.060 |
Why?
|
Receptor, Fibroblast Growth Factor, Type 1 | 1 | 2024 | 256 | 0.050 |
Why?
|
Receptor, Fibroblast Growth Factor, Type 2 | 1 | 2024 | 211 | 0.050 |
Why?
|
Child | 5 | 2023 | 79782 | 0.050 |
Why?
|
New South Wales | 1 | 2021 | 68 | 0.050 |
Why?
|
Proto-Oncogene Proteins c-ret | 1 | 2023 | 225 | 0.050 |
Why?
|
Receptors, Thyroid Hormone | 1 | 2022 | 199 | 0.050 |
Why?
|
Tomography, X-Ray Computed | 1 | 2024 | 20499 | 0.050 |
Why?
|
Child, Preschool | 2 | 2021 | 42045 | 0.050 |
Why?
|
Area Under Curve | 1 | 2024 | 1632 | 0.040 |
Why?
|
Fanconi Anemia | 1 | 2021 | 324 | 0.040 |
Why?
|
Histocytochemistry | 1 | 2019 | 699 | 0.040 |
Why?
|
United States | 2 | 2023 | 71902 | 0.040 |
Why?
|
Mucous Membrane | 1 | 2021 | 657 | 0.040 |
Why?
|
Magnetic Resonance Imaging | 1 | 2024 | 36270 | 0.030 |
Why?
|
Predictive Value of Tests | 2 | 2023 | 15207 | 0.030 |
Why?
|
Europe | 1 | 2021 | 3413 | 0.030 |
Why?
|
Fibrosis | 1 | 2022 | 2038 | 0.030 |
Why?
|
Consensus | 1 | 2021 | 3097 | 0.020 |
Why?
|
Neoplasm Invasiveness | 1 | 2019 | 3591 | 0.020 |
Why?
|
Proto-Oncogene Proteins B-raf | 1 | 2019 | 2052 | 0.020 |
Why?
|
Drug Resistance, Neoplasm | 1 | 2024 | 5253 | 0.020 |
Why?
|
Alcohol Drinking | 1 | 2021 | 4019 | 0.020 |
Why?
|
Genomics | 1 | 2023 | 5788 | 0.020 |
Why?
|
Evidence-Based Medicine | 1 | 2019 | 3670 | 0.020 |
Why?
|
Risk Factors | 2 | 2023 | 73708 | 0.020 |
Why?
|
Genotype | 1 | 2019 | 12951 | 0.020 |
Why?
|
DNA-Binding Proteins | 1 | 2022 | 9574 | 0.010 |
Why?
|
Age Factors | 1 | 2021 | 18326 | 0.010 |
Why?
|
Reproducibility of Results | 1 | 2021 | 20037 | 0.010 |
Why?
|
Time Factors | 1 | 2023 | 39811 | 0.010 |
Why?
|
Risk Assessment | 1 | 2021 | 23816 | 0.010 |
Why?
|
Cohort Studies | 1 | 2019 | 41190 | 0.010 |
Why?
|
Treatment Outcome | 1 | 2019 | 64242 | 0.010 |
Why?
|
Concepts
(101)
Derived automatically from this person's publications.
Explore
_
Co-Authors
(22)
People in Profiles who have published with this person.
Explore
_
Similar People
(59)
People who share similar concepts with this person.
Explore
_
Same Department
People in same department with this person.
Explore
_